Drugs / Pelubiprofen
Pelubiprofen
also known as
PELUBI tab. · 2-[4-(oxocyclohexylidenemethyl)-phenyl]propionic acid · CS-670 · Pelubi · Pelubi CR · Pelubiprofen IR · Pelubiprofen SR · Pelubiprofene · +2 more
Trials 9 · a red edge is where a trial was stopped
Also used as a comparator or background therapy in 4 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01870102 Comparator | ? → Aug 2013 | — | Daewon Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03424707 Comparator | Mar → Aug 2016 | — | Daewon Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT02375633 Comparator | Apr → Nov 2014 | chronic pain syndrome | Daewon Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT02682524 Comparator | Aug 2015 → Mar 2016 | osteoarthritis, knee | Daewon Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 14 cited values
Every value below carries the sentence it was read from. 15 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | pelubiprofen | “DW-1021 is a fixed-dose combination tablet containing Pelubiprofen 45 mg and Tramadol 45.9 mg (as a salt), formulated as a controlled-release film-coated tablet.” NCT07032558 ↗12“A fixed-dose combination controlled release film-coated tablet containing pelubiprofen 45 mg and tramadol 45.9 mg (salt form)” NCT07060209 ↗ “pelubiprofen 30mg (PELUBI tab.)” NCT05214677 ↗ “pelubiprofen 25mg” NCT05214690 ↗ |
| Known as | 2-[4-(oxocyclohexylidenemethyl)-phenyl]propionic acid | “Anti-inflammatory effect of pelubiprofen, 2-[4-(oxocyclohexylidenemethyl)-phenyl]propionic acid, mediated by dual suppression of COX activity and LPS-induced inflammatory gene...” PMID 21809372 ↗ Dec 2011 |
| Known as | CS-670 | ChEMBL registry synonym — accepted as the source's own label CHEMBL69308 ↗ |
| Known as | Pelubi | “Pelubi(pelubiprofen)” NCT03424707 ↗ |
| Known as | Pelubi CR | “The reference treatment consists of two separate controlled-release film-coated tablets: Pelubi CR (Pelubiprofen 45 mg) and Zytram CR (Tramadol HCl 75 mg).” NCT07032558 ↗ |
| Known as | PELUBI tab. | “pelubiprofen 30mg (PELUBI tab.)” NCT05214690 ↗1“pelubiprofen 30mg (PELUBI tab.)” NCT05214677 ↗ |
| Known as | Pelubiprofen IR | “Pelubiprofen IR (Pelubiprofen 30mg) TID” NCT01870102 ↗ |
| Known as | Pelubiprofen SR | “Pelubiprofen SR (Pelubiprofen 45 mg) BID” NCT01870102 ↗ |
| Known as | Pelubiprofene | ChEMBL registry synonym — accepted as the source's own label CHEMBL69308 ↗ |
| Known as | Pelubiprofeno | ChEMBL registry synonym — accepted as the source's own label CHEMBL69308 ↗ |
| Known as | RS-2131 | ChEMBL registry synonym — accepted as the source's own label CHEMBL69308 ↗ |
| Action | Inhibit | “pelubiprofen potently diminished PGE(2) productions through inhibition of COX enzyme activity” PMID 21809372 ↗ Dec 2011 |
| Modality | Small molecule | — CHEMBL69308 ↗ |
| Route | Oral | “It is administered as a single oral dose with 150 mL of water under fasting conditions for the evaluation of pharmacokinetics in healthy adult male volunteers.” NCT07032558 ↗ |